Keywords
creatinine
liver cirrhosis
hepatorenal syndrome
How to Cite
Abstract
Introduction: During the cirrhotic patient’s disease, renal failure is a poor prognostic event.
Purpose: Knowing the risk factors for AKI in these patients given by the presence of infectious processes, loss of fluids due to hemorrhage, gastrointestinal or kidney, and nephrotoxic agents are essential for initiating therapeutic measures and prophylactic actions.
Methodology: A bibliographic search was carried out in the PubMed, EMBASE, Scopus and academic Google databases, using the terms MeSH acute renal failure, creatinine, liver cirrhosis, hepatorenal syndrome. Original articles, meta-analyzes, case reports, case series and literature reviews were obtained, choosing 16 documents for the preparation of this review.
Results: The new criteria defined by the International Ascites Club (AKI-IAC), which eliminate urinary out put, are determined by an increase in serum creatinine?0.3 mg / dL in less than 48 hours and improve the prognosis, allowing timely interventions.
Conclusions: Creatinine continues to be the most widely used biomarker in AKI, even in cirrhotic patients, despite its multiple limitations. A dynamic criterion modified from the AKIN criteria becomes the gold standard for the diagnosis of AKI in cirrhosis.
References
Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology. 1996;23(1):164-76. https://doi.org/10.1002/hep.510230122
Sherman DS, Fish DN, Teitelbaum I. Assessing renal function in cirrhotic patients: problems and pitfalls. American journal of kidney diseases. 2003;41(2):269-78. https://doi.org/10.1053/ajkd.2003.50035
Caregaro L, Menon F, Angeli P, Amodio P, Merkel C, Bortoluzzi A, et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Archives of internal medicine. 1994;154(2):201-5. https://doi.org/10.1001/archinte.1994.00420020117013
Spencer K. Analytical reviews in clinical biochemistry: the estimation of creatinine. Annals of clinical biochemistry. 1986;23(1):1-25. https://doi.org/10.1177/000456328602300101
Wong F, Nadim MK, Kellum JA, Salerno F, Bellomo R, Gerbes A,et al. Working partyproposal for a revised classication system of renal dysfunction in patients with cirrhosis.Gut. 2011:60(5):702-9. https://doi.org/10.1136/gut.2010.236133
Angeli P, Ginès P, Wong F, Bernardi M, Boyer TD, Gerbes A,et al. Diagnosis and manage-ment of acute kidney injury in patients with cirrhosis: revised consensusrecommendationsof the International Club of Ascites. J Hepatol. 2015;62(4):968-74. https://doi.org/10.1016/j.jhep.2014.12.029
Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure-denition, out-come measures, animal models, uid therapy and information technology needs: the SecondInternational Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.Crit Care. 2004 ag;8(4):R204-12. https://doi.org/10.1186/cc2872
Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, et al. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney international supplements. 2012;2(1):1-138.
Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatmentof hepatorenal syndrome in cirrhosis. Postgrad Med J. 2008;84(998):662-70. https://doi.org/10.1136/gut.2006.107789
Garzia P, Ferri G, Ilardi M, Messina F, Amoroso A. Pathophysiology, clinical features and management of hepatorenal syndrome. Eur Rev Med Pharmacol Sci. 1998;2(5):181-4.
Ginès P, Arroyo V, Vargas V, Planas R, Casafont F, Panés J,et al. Paracentesis withintravenous infusion of albumin as compared with peritoneovenous shunting in cirrho-sis with refractory ascites. N Engl J Med. 1991;325(12):829-35. https://doi.org/10.1056/NEJM199109193251201
Angeli P, Fasolato S, Mazza E, Okolicsanyi L, Maresio G, Velo E, Galioto A,et al. Combinedversus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis:results of an open randomized clinical trial. Gut. 2010;59:98-104. https://doi.org/10.1136/gut.2008.176495
Angeli P, Gatta A, Caregaro L, Menon F, Sacerdoti D, Merkel C,et al. Tubular site of renalsodium retention in ascitic liver cirrhosis evaluated by lithium clearance. Eur J Clin Invest.1990;20(1):111-7. https://doi.org/10.1111/j.1365-2362.1990.tb01800.x
Joannidis M, Metnitz B, Bauer P, Schusterschitz N, Moreno R, Druml W,et al.Acute kid-ney injury in critically ill patients classied by AKIN versus RIFLE using the SAPS 3 database. Intensive Care Med. 2009;35(10):1692-702. https://doi.org/10.1007/s00134-009-1530-4
Tu KH, Jenq CC, Tsai MH, Hsu HH, Chang MY, Tian YC,et al. Outcome scoring systemsfor short-term prognosis in critically ill cirrhotic patients. Shock. 2011;36(5):445- 50. https://doi.org/10.1097/SHK.0b013e31822fb7e2
Tsien CD, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis. Gut.2013;62(1):131-7. https://doi.org/10.1136/gutjnl-2011-301255
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.